NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Veru Inc. VERUTwist Bioscience Corp TWSTand Leidos Holdings Inc. LDOS. Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

Veru Inc. VERU

On November 10, 2022, Veru issued a press release announcing that the U.S. Food and Drug Administration’s Advisory Committee on Lung Allergy Drugs (the “Advisory Committee”) had voted against granting an emergency use authorization for the Company’s product Sabizabulin Treatment of moderate to severe hospitalizations for COVID-19 patients who are at high risk for acute respiratory distress syndrome. Specifically, the Advisory Committee voted 8 to 5 that the known and potential benefits of sabizabulin do not outweigh the known and potential risks.

As a result of this news, Veru’s share price fell sharply during intraday trading on November 10, 2022.

For more information on the Instil investigation, visit: https://bespc.com/cases/VERU

Twist Bioscience Corp TWST

Prior to the market open on November 15, 2022, Scorpion Capital published a negative report on Twist entitled “A Cash-Burning Inferno That Is Not a Going Concern, Operating a Ponzi-Like Scheme That Will End In Bankruptcy. Just Another ‘Synthetic Biology’ scam, this time with an absurd ‘silicon DNA chip’ and financial data so bogus it could be criminal. Price target: $0.” The report claims that Twist is “a ticking time bomb that we believe is resorting to a Worldcom-like accounting fraud” and “several competitors internally refer to Twist’s price dumping and customer subsidy scheme as “Ponzi.”

In early morning trading on November 15, 2022, Twist’s stock price is down $11.42 per share to $26.59, down 30.0%.

For more information on the Twist investigation, visit: